Pancreatic Cancer Laboratory Findings 

Illustrates Domains

LB

Illustrates Variables

SPDEVID
LBNAM
LBSPEC
LBMETHOD
 LBTPT


Content

This example shows laboratory tests that may be performed on subjects with pancreatic cancer. This example trial enrolled subjects who had prior surgery for pancreatic cancer. The sponsor collected historical information on the CA 19-9 marker, prior to any pancreatic surgery, as well as post-surgery. The sponsor defined time points to represent the historic values that were obtained prior to and post-surgery. The protocol provided details on the allowable time frames for the collection of these historical pre- and postoperative levels; these details are not provided in this example.

If using LBLOINC, the sponsor is expected to provide the dictionary name and version used to map the terms, utilizing Define-XML external codelist attributes.

lb.xpt

lb.xpt

Row

STUDYID

DOMAIN

USUBJID

SPDEVID

LBSEQ

LBTESTCD

LBTEST

LBCAT

LBORRES

LBORRESU

LBORNRLO

LBORNRHI

LBSTRESC

LBSTRESN

LBSTRESU

LBNAM

LBSPEC

LBMETHOD

VISITNUM

VISIT

VISITDY

LBDTC

LBTPTLBTPTNUMLBTPTREFLBRFTDTC
1PACA013LB1300Com XX Electrochemiluminescence Immunoassay1CA19_9AGCancer Antigen 19-9CHEMISTRY37U/mL0

35

3737U/mLVENDOR ASERUMELECTROCHEMILUMINESCENCE IMMUNOASSAY10SCREENING-12019-08-01PRE- SURGERY1PANCREATIC SURGERY DATE2019-08-15
2PACA013LB1300Com XX Electrochemiluminescence Immunoassay2CA19_9AGCancer Antigen 19-9CHEMISTRY20U/mL0352020U/mLVENDOR ASERUMELECTROCHEMILUMINESCENCE IMMUNOASSAY10SCREENING-12019-10-17POST- SURGERY2PANCREATIC SURGERY DATE2019-08-15
3PACA013LB1300Com XX Electrochemiluminescence Immunoassay3CA19_9AGCancer Antigen 19-9CHEMISTRY22U/mL0362222U/mLVENDOR ASERUMELECTROCHEMILUMINESCENCE IMMUNOASSAY10SCREENING-1

2020-01-05





4PACA013LB1300
4FATFatCHEMISTRY15%0201515%VENDOR ASTOOL
10SCREENING-12020-01-05



5PACA013LB1300
5CEACarcinoembryonic AntigenCHEMISTRY7.0ug/L03.07.07.0ug/LVENDOR ASERUMIMMUNOASSAY 10SCREENING-12020-01-05